Update on invirase resistance
- WHO/UNAIDS HIV vaccine initiative calls for accelerated research to build on trial accomplishments. // Weekly Epidemiological Record;2/28/2003, Vol. 78 Issue 9, p62
Reveals that the World Health Organization/United Nations AIDS HIV vaccine initiative calls for accelerated research to build on trial accomplishments. Need for expansion of existing prevention efforts; Updates in companies developing AIDS/HIV vaccines.
- New AIDS vaccine offers cautious hope. Wareham, Hannah Clay // Bay Windows;10/1/2009, Vol. 27 Issue 41, p1
The article presents information on a new HIV vaccine, RV 144, which prevented new infections in 31.2 percent of the 16,000 Thai volunteers in a study.
- The magic bullet. Wells, Ken R. // Advocate;11/28/95, Issue 695, p40
Looks at the lack of funds for the development of vaccines for the prevention of HIV infection. Decision of pharmaceuticals and private investors to divert funds to the development of therapeutic approaches for the disease; Profitability of a cure for AIDS instead of a means of prevention.
- Safety and Immunogenicity of a Canarypox-Vectored HIV Type 1 Vaccine with or without gp120. Belshe, Robert B.; Stevens, Cladd; Gorse, Geoffrey J.; Buchbinder, Susan; Sheppard, Haynes; Stablein, Donald; Self, Steve; McNamara, James; Frey, Sharon; Flores, Jorge; Excler, Jean Louis; Klein, Michel; El Habib, Raphaelle; Duliege, Anne-Marie; Harro, Clayton; Corey, Lawrence; Keefer, Michael; Mulligan, Mark; Wright, Peter; Celum, Connie // Journal of Infectious Diseases;5/1/2001, Vol. 183 Issue 9, p1343
Presents a study which examined the safety and immunogenicity of a canarypox vector HIV type 1 vaccine with or without gp120 boosting. Methodology; Results; Discussion.
- Amsterdam reports triple combination results. // AIDS Patient Care & STDs;Feb1997, Vol. 11 Issue 1, p35
Reports on the result of the three antiviral agents for HIV in Amsterdam, Netherlands. Use of AZT, ritonavir and 3TC.
- CAESAR shows survival benefit. // AIDS Patient Care & STDs;Feb1997, Vol. 11 Issue 1, p35
Reports on the result of the CAESAR study for HIV conducted in Canada, Australia, Europe and South Africa. Combination of 3TC plus loverine, placebo and AZT.
- Good news on AIDS. Costello, Emily // Science World;2/9/96, Vol. 52 Issue 9, p6
Reports on two discoveries in the battle against AIDS. Persistence of good health of people in Australia for 14 years after being infected with HIV; Possible use of genetically defective strain of HIV as vaccine; Effectiveness of a drug in stopping simian immuno-deficiency virus (SIV);...
- ...big steps for a young group. Dove, Alan // Nature Medicine;Jan1999, Vol. 5 Issue 1, p5
Discusses the growth of the New York-based International AIDS Vaccine Initiative (IAVI). International recognition as an advocacy group for HIV/AIDS vaccine research and development; Organization's reliance on annual contributions since it does not have an endowment; Famous people who have made...
- Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Cafaro, Aurelio; Caputo, Antonella; Fracasso, Claudio; Maggiorella, Maria T.; Goletti, Delia; Baroncelli, Silvia; Pace, Monica; Sernicola, Leonardo; Koanga-Mogtomo, Martin L.; Betti, Monica; Borsetti, Alessandra; Belli, Roberto; �kerblom, Lennart; Corrias, Franco; Butt�, Stefano; Heeney, Jonathan; Verani, Paola; Titti, Fausto; Ensoli, Barbara // Nature Medicine;Jun99, Vol. 5 Issue 6, p643
Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show...